Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Rain Oncology Inc. Common Stock (RAIN)

Pharmaceutical Preparations

https://www.rainoncology.com

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

8000 JARVIS AVENUE, SUITE 204
NEWARK, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/23/2021

Market Cap

44,014,599

Shares Outstanding

36,390,000

Weighted SO

36,384,709

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

AVRO --.--%

CWBR --.--%

OCEA --.--%

ENVB --.--%

ELEV --.--%

HEPA --.--%

ZURA --.--%

EFTR --.--%

Beta

0.2730

Last Div

0.0000

Range

0.82-11.32

Chg

-0.0200

Avg Vol

238293

Mkt Cap

44014599

Exch

NASDAQ

Country

US

Phone

510 953 5559

DCF Diff

-0.9939

DCF

2.2039

Div Yield

0.0000

P/S

0.0000

EV Multiple

-0.1009

P/FV

0.6519

Div Yield %

0.0000

P/E

-0.6199

PEG

0.2738

Payout

0.0000

Current Ratio

5.5824

Quick Ratio

5.3776

Cash Ratio

2.5773

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0036

ROA

-0.8652

ROE

-0.8152

ROCE

-1.1336

NI/EBT

0.9826

EBT/EBIT

0.9432

EBIT/Rev

0.0000

Debt Ratio

0.0056

D/E

0.0068

LT Debt/Cap

0.0000

Total Debt/Cap

0.0067

Int Coverage

42.7506

CF/Debt

-144.2018

Equity Multi

1.2154

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.8077

FCF/Share

-1.8733

Cash/Share

2.1256

OCF/Sales

0.0000

FCF/OCF

1.0363

CF Coverage

-144.2018

ST Coverage

-144.2018

CapEx Coverage

-27.5325

Div&CapEx Cov

-27.5325

P/BV

0.6519

P/B

0.6519

P/S

0.0000

P/E

-0.6199

P/FCF

-0.6459

P/OCF

-0.6694

P/CF

-0.6694

PEG

0.2738

P/S

0.0000

EV Multiple

-0.1009

P/FV

0.6519

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 13, 18:05 Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights GlobeNewswire Inc. Dec 13, 18:05 Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights GlobeNewswire Inc. Dec 13, 18:05 Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights GlobeNewswire Inc. Dec 13, 18:05 Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights GlobeNewswire Inc. Dec 13, 18:05 Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

Revenue Product Segmentation